Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
NCT04767373
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
3632
Enrollment
INDUSTRY
Sponsor class
Conditions
Respiratory Syncytial Virus Infection
Interventions
BIOLOGICAL:
Clesrovimab
DRUG:
Placebo
Sponsor
Merck Sharp & Dohme LLC